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ly, with an individual’s way of thinking, with 
his behavior, with the sleep-wake cycle, as 
well as with everyday social and working 
activities. The severity of the illness and, 
consequently, the improvement of symptoms 
after therapy are generally measured through 
rating scales for depression which have been 
validated worldwide. Among the most com-
mon, are the Hamilton Depression Scale 
(HAM-D), the Montgomery and Asberg De-
pression Rating Scale (MADRS), and the 
Clinical Global Impression Scale (CGI-S). 
Different kinds of treatments, including med-
icines, psychotherapy, and electroconvulsive 
therapy (ECT) are available.
In particular, as far as medicines are con-
cerned, there are several specific classes of 
proven efficacy, but these need to be taken 
for long periods of time. Further, they must 
often be combined in order to have a thera-
peutic effect on the various symptoms of the 
disorder and are characterized by side- and/or 
adverse effects which, although often limited 
to the first few weeks of treatment, influence 
patient compliance and require a change of 




This study was meant to assess the degree of 
innovation for agomelatine 25 mg coated tab-
lets, a new medicine to be used in major de-
pression therapy. To this end, the Innovation 
Assessment Algorithm (IAA), developed and 
presented by Prof. Luciano Caprino and Dr 
Pierluigi Russo during the six-month Italian 
Presidency of the European Union (2003), 
was utilized. The Algorithm, published in 
Drug Discovery Today in 2006 [1], considers 
the innovative quality of a medicine not as a 
single, distinct property, but as a combination 
of several properties that may be represented 
like a decision tree. Each branch of the tree, 
corresponding to a property connected with 
innovation, is assigned a fixed numerical val-
ue. The sum of these values establishes the 
degree of innovation of the medicine.
Major depression
Major depression is a serious disorder which 
affects every year approximately 5% of the 
adult population. It presents features of per-
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ABSTRACT
Aim: the aim of this study was to assess the innovative quality of a medicine based on agomelatine, authorized by the 
European Commission through a centralized procedure on 19th February 2009 and distributed in Italy under the brands 
Valdoxan® and Thymanax®.
Methodology: the degree of innovation of agomelatine was determined through the Innovation Assessment Algorithm 
(IAA), which considers the innovative quality of a medicine as a combination of multiple properties. The algorithm may be 
represented as a decision tree, with each branch corresponding to a property connected with innovation and having a fixed 
numerical value. The sum of these values establishes the degree of innovation of the medicine. The IAA is articulated in two 
phases: the first assesses the efficacy of the drug based on the clinical trials presented in support of the registration applica-
tion (IAA-efficacy); the second reconsiders the degree of innovation on the basis of the efficacy and safety data resulting 
from clinical practice once the drug has been placed on the market (IAA-effectiveness).
Results and conclusions: the score obtained for agomelatine was 592.73 in the efficacy phase and 291.3 in the effectiveness 
phase. The total score for the two phases was 884, which is equivalent to a good degree of innovation for the molecule.
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According to the World Health Organization, 
major depression is the most frequent cause 
of disability in the world, afflicting individu-
als aged 5 and above.
Major depression is characterized by a series 
of signs and symptoms:
 - persistently sad or irritable mood;
 - changes in sleep patterns (insomnia, wak-
ing up early in the morning);
 - changes in appetite and body weight 
(more often weight loss but also weight 
gain);
 - loss of concentration, memory and atten-
tion;
 - slow movements or agitation;
 - loss of interest or pleasure in activities 
that are normally pleasurable;
 - feelings of guilt, uselessness, hopeless-
ness and emptiness;
 - recurring thoughts of death or suicide;
 - physical symptoms that do not respond to 
treatment, such as headaches, digestive 
problems, persistent pains.
In most cases it is a recurring and episodic 
disease while it is one of the pathologies with 
the highest social and individual cost.
The medicine
Valdoxan®/Thymanax® is a medicine based 
on agomelatine, a synthetic analogue of 
melatonine. Its antidepressive action is 
performed through the melatonergic MT1 
and MT2 receptor agonists and the sero-
tonin 5-HT2C receptor antagonist activ-
ity. Valdoxan®/Thymanax® was registered 
in Europe through a centralized procedure 
and was authorized (February 2009) for the 
treatment of major depressive disorders in 
adults.
The recommended dosage is 25 mg/day. The 
dosage may be increased to 50 mg/day if 
there is no improvement of symptoms after 2 
weeks. A treatment lasting at least six months 
is recommended.
The undesired side effects are generally mild 
or moderate, transitory in nature, and pres-
ent especially during the first two weeks of 
treatment. The most common are headaches, 
nausea, dizziness, drowsiness, increase in he-
patic enzymes, and hyperhidrosis.
The algorithm
The IAA is articulated in two phases: the 
first assesses the efficacy of the drug based 
on the clinical trials presented to support the 
registration application (IAA-efficacy); the 
second reconsiders the degree of innovation 
on the basis of the efficacy and safety data 
deriving from clinical practice once the drug 
has been placed on the market (IAA-effec-
tiveness).
As far as IAA-efficacy is concerned, access 
to the algorithm may occur through three dif-
ferent access paths (roots), which represent 
as many degrees of innovation, in a gradually 
descending order:
 - therapeutic innovation;
 - common innovation;
 - industrial innovation.
Moving along any one of these paths leads 
to successive decision nodes, from which 
multiple alternative choices (tree branches) 
branch off, each one associated with numeri-
cal coefficients progressively decreasing ac-
cording to the position of the decision node 
on the branch. For each root, a first, second 
and third level of development is provided 
for, and for each level several articulations or 
branches are provided which relate to:
 - the drug’s action mechanism;
 - the social impact of the disorder;
 - the type of research design employed;
 - the types of objectives achievable for the 
patient in terms of recovery, management 
of the disorder, improvement of symp-
toms, improved tolerance of the medi-
cine, improved risk-benefit ratio;
 - typology of criteria for the assessment of 
clinical results obtained: hard endpoints 
and surrogate endpoints, quality of life.
Proceeding within the algorithm from left 
to right the assessment can be completed 
and a numerical value can be obtained 
which represents the sum of numerical co-
efficients attributed to each decision branch 
selected, an expression of the medicine’s 
degree of innovation in the pre-registration 
phase.
After this phase is completed, we can then as-
sess the medicine after its placement on the 
market (IAA-effectiveness). The properties 
evaluated during this phase are:
 - the types and purposes of post-registra-
tion trials;
 - in a chronic disease, the length of time of 
the trials; in an acute/sub-acute disease, 
the number of patients enrolled;
 - the types of criteria for assessing clinical 
results obtained (hard endpoints and sur-
rogate endpoints, quality of life);
 - the types of objectives achievable for the 
patient in terms of recovery, management 
of the disorder, improvement of symp-
toms, improved tolerance of the drug, im-
proved risk-benefit ratio;
 - the selection criteria for patients enrolled;
 - the size of the clinical trials (Multicenter, 
National or International);
 - the severity and frequency of harmful 
side effects registered by the pharmaco-
vigilance system and in the context of ef-
fectiveness studies.
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In this case too, a score will be obtained that 
must be added to that obtained during the first 
phase.
In conclusion, the innovation assessment of a 
medicine through the IAA allows us to:
 - bind the innovation value to the deter-
mination of the clinical efficacy (on the 
pre-registration level) and of the clinical 
effectiveness (almost always in the post-
marketing phase);
 - express, through a numerical value, the 
innovation contribution made by a drug. 
This value can be established on the basis 
of a decision algorithm capable of taking 
into consideration the various elements 
that contribute to innovation;
 - utilize it, in full or in part, both for the 
purpose of Authorization of Placement 
on the Market for a medicine, and for 
re-assessment of the medicine’s extent 
of innovation during the post-marketing 
period.
Innovation assessment 
by means of the IAA
Measurement of the degree of innovation 
is performed by using a specific software, 
downloadable from the site of the SIFEIT 
– Italian Association for Research on the 
Economics and Ethics of Medicines and 
Therapeutic Procedures, which enables us 





Access to the algorithm occurs through selec-
tion of the general property expressed by the 
three initial degrees of innovation (roots). In 
Figure 1, the diagram relating to the first lev-
el of the decision tree is shown.
For agomelatine, access to the algorithm oc-
curs through branch B of therapeutic innova-
tion: in fact, agomelatine is a new chemical 
entity which represents the prototype of a 
new class, active against a pathology (ma-
jor depression) for which pharmacological 
therapies already exist. In fact, those already 
present on the market are:
 - tricyclic antidepressants (TCA);
 - monoaminooxidase inhibitors (IMAO);
 - selective serotonin reuptake inhibitors 
(SSRI);
 - selective noradrenaline reuptake inhibi-
tors (SNRI);
 - dopamine reuptake blocking drugs.
Second level
Level 2.1 – mechanism of action
Accessing the IAA through branch B, the first 
aspect to assess is the mechanism of action 
for which two alternatives are possible (Fig-
ure 2). In the case of agomelatine the mecha-
nism of action is new, since it is a melatoner-
Figure 1. IAA-efficacy: first level of the decision tree
ATC = Anatomic Therapeutic Chemical; CE = chemical entity
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gic agonist (acts on MT1 and MT2 receptors) 
and, at the same time, is a serotonin 5-HT2C 
receptor antagonist.
Its antidepressant action depends on its activ-
ity on both types of receptors and represents 
a new concept for the treatment of depression 
[2-4]. In addition, the molecule has shown 
anxiolytic effects as well as effects of resyn-
chronizing circadian rhythms, due to the mel-
atoninergic activity.
Level 2.2 – typology of the disorder
The second node of the first level of the deci-
sion tree (Figure 3) refers to the social impact 
Figure 2. IAA-efficacy, level 2.1: action mechanism
of the disease for which the drug is indicated. 
Due to the high degree of disability and its 
high social and individual cost, major depres-
sion falls within the definition of an elevated 
social impact disease.
Third level
Level 3.1 – therapeutic indications
Proceeding along the decision tree to the 
third level, the first assessment to be made 
(Figure 4) relates to the possibility of multi-
ple therapeutic indications within the first 
level of ATC. Agomelatine has only one indi-
cation: the treatment of major depression epi-
sodes in adults.
Level 3.2 – type of clinical 
study designed employed
The level 3.2 algorithm provides for selection 
of the branch with regard to the types of trials 
and requires a guideline opinion (excellent, 
sufficient, poor) on the performance and/or 
data contained within them (Figure 5). 
The main clinical trial documentation on 
agomelatine involves over 4,000 subjects 
diagnosed with major depression who took 
agomelatine. It involves randomized, double 
blind trials, mostly multicenter, performed 
vs. a placebo or vs. an active drug.
Trials performed vs. placebo include a study 
for verifying the minimum effective dose 
(dose-finding study) [5,6]: a short term (8 
weeks), randomized, double blind study per-
formed on 711 patients. Three different dos-
ages of agomelatine were compared (1, 5, 
and 25 mg) using paroxetine as an internal 
control with the variation of the score on the 
HAM-D scale used as the main efficacy mea-
surement. The lowest doses proved to have 
an effect similar to the placebo. The 25 mg 
dose was statistically more effective than the 
placebo, both compared to the HAM-D score 
and compared to other assessment criteria 
(Montgomery-Asberg Depression Rating 
Scale, Clinical Global Impression-Severity 
of Illness). There were no differences be-
tween agomelatine and paroxetine. Two 
studies with agomelatine 25 mg or 50 mg 
vs. placebo [6-8], both short term (six week) 
multicenter, randomized, double blind, are 
included: the first [7] performed on 211 sub-
jects, the second [8] on 235 subjects. For 
subjects who showed no improvement with 
agomelatine 25 mg at two weeks, the dose 
was increased to 50 mg through an electronic 
system that allowed the double blind status 
to be maintained. In this case too, the main 
assessment was based on the variation of the 
score on the HAM-D scale. In both studies, 
agomelatine was significantly more effective 
than the placebo.
Figure 3. IAA-efficacy, level 2.2: typology of the disorder
Figure 4. IAA-efficacy,  level 3.1: therapeutic indications
ATC = Anatomic Therapeutic Chemical
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In the CHMP Assessment Report presented to 
the EMA [9], three more short term studies 
were described, all with active internal con-
trol (paroxetine or fluoxetine) in which there 
was no statistically significant difference be-
tween agomelatine and the placebo. In this 
regard, the discussion reports that agomela-
tine probably has a lower efficacy than other 
antidepressants and that further studies, on a 
larger scale, are necessary to confirm the ef-
ficacy of the medicine. Lastly, a specific study 
was performed to assess maintenance of the 
pharmacological effect and the time elapsed 
until reappearance of the disorder [10]: a long 
term study (for 24 weeks after a period of 8-10 
weeks of openly taking the drug), multicenter, 
randomized, double blind, on 339 responders 
in the first phase; the assessment was based 
on the time elapsed until reappearance of the 
disorder. The results show a statistically sig-
nificant difference in the time until relapse, in 
favor of agomelatine.
The symptoms evaluated through the HAM-D 
scale reappeared in 21% of the patients treated 
with agomelatine over the 24 weeks (34 out of 
165), compared with 41% of the patients treat-
ed with the placebo (72 out of 174). No differ-
ences were reported between subjects with se-
rious and/or moderate/mild depression. A long 
term study, preceding the one described above, 
did not show statistically significant differenc-
es between agomelatine and the placebo.
Among the studies performed vs. active 
medicines, we report two studies vs. venla-
faxine [11,12]: short term (6 weeks for the 
first, 12 weeks for the second), multicenter, 
randomized, double blind studies. The first 
[11] involved 332 subjects (165 treated with 
agomelatine 25-50 mg, 167 with venlafax-
ine 75-150 mg). The purpose of the study 
was to assess the improvement of sleep pat-
terns (understood as falling asleep, quality 
of sleep, number of times patient wakes up 
at night), measured through an appropriate 
scale, the Leeds Sleep Evaluation Question-
naire (LSEQ) and the total antidepressant ef-
fect, measured by the HAM-D and the CGI-
S. Because agomelatine is a drug that also 
acts on the sleep-wake cycle, the beneficial 
effect is without a doubt better for this drug 
than for the comparison drug. The improve-
ment of the quality of sleep was also impor-
tant for the antidepressant effect. The second 
study [12], involved 277 subjects (137 treat-
ed with agomelatine 50 mg, 140 with venla-
faxine 75-50 mg). The purpose of the study 
was to assess the harmful side effects typical 
for most antidepressant drugs, the deteriora-
tion of sexual functioning (through the Sex 
FX scale), and the antidepressant efficacy 
(through the MADRS, CGI scale). Agomela-
tine use results in a statistically lower occur-
rence of sexual disorders compared to venla-
faxine. There is no significant difference in 
the decreased MADRS score. A study vs. ser-
traline [13] was also performed: a short term 
(6 weeks), multicenter, randomized, double 
blind study on 313 subjects, (154 agomela-
tine 25-50 mg vs. 159 sertraline 50-100 mg); 
the principal assessment was based on the 
sleep-wake cycle and on the HAM-D scale. 
The results show a statistically significant 
antidepressant effect for agomelatine, calcu-
lated on different scores of the HAM-D scale, 
starting from the second week of treatment.
As stated above, the branch of the decision 
tree to be selected for level 3.2 has to do with 
double blind studies. The results obtained are 
deemed sufficient, although it may be neces-
sary to perform in depth clinical trials in or-
der to verify the efficacy of the drug, for use 
with elderly patients and for any possible in-
teractions or effects that can only be verified 
in clinical practice.
Level 3.3 – population 
involved in the studies
This level assigns a score relative to the age 
groups of the population involved in the stud-
ies performed (Figure 6): as stated above, 
subjects involved in studies with agomelatine 
are between the ages of 18 and 60 years of age 
(adults). In the CHMP Assessment Report 
presented to the EMA [9], a trial performed 
on subjects > 65 years of age is described 
which did not show a significant difference 
between agomelatine and the placebo. The 
desirability of performing a post-registration 
study for these types of subjects is expressed. 
The branch to follow on the decision tree is 
that relating only to the adult population.
Level 3.4 – types of achievable objectives
This level allows selection between treatment 
or management of the disease (in the case of 
chronic disease) and the improvement of 
symptoms (Figure 7). From what has been 
Figure 5. IAA-efficacy, level 3.2: types of clinical studies
RCT = Randomized Clinical Trial
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reported, agomelatine appears to have signif-
icantly greater therapeutic efficacy compared 
with the placebo or with the comparison drug 
in the treatment of Major Depression, in ad-
dition to controlling some of its specific 
symptoms. At this level of the algorithm, the 
selected branch is therefore that having to do 
with treatment of the disease.
This level assigns a score based on the types 
of outcomes (Figure 8) and in this instance 
too a guideline opinion is required (excellent, 
sufficient, poor).
Figure 6. IAA-efficacy, level 3.3: types of populations involved in the clinical trials
Figure 7. IAA-Efficacy, level 3.4: typology of achievable objectives
RCT = Randomized Clinical Trial
Figure 8. IAA-Efficacy – level 3.5: type of clinical outcome obtained
RCT = Randomized Clinical Trial
Level 3.5 – type of clinical 
outcome obtained
From what is reported above, we can see that 
agomelatine appears to be effective in major 
depression, both in terms of treatment of the 
disease and in preventing its recurrence, as 
well as in terms of improvement of quality of 
life (normalization of the sleep-wake cycle, 
improvement of sexual activity). Therefore, 
the branch to select is that relating to hard 
end-points and quality of life (HE + QoL). 
The results were deemed sufficient.
IAA-effectiveness
The structure of the algorithm in the second 
phase is similar to that of IAA-efficacy, with 
several levels corresponding to as many char-
acteristics that contribute to the innovation 
value of the drug, based on post-marketing 
clinical trials. IAA-effectiveness starts from a 
single branch defined by the score obtained at 
the end of the assessment of the IAA-efficacy 
route, which develops on three levels. In this 
case too, a score will be obtained that must be 
added to the one obtained in the first phase.
First level
This level has to do with the presence or 
absence of clinical trials published or per-
formed after authorization for placement on 
the market was obtained. Five new trials are 
presented, of which one is versus placebo, 
three versus a comparison drug, and one ver-
sus both a placebo and a comparison drug.
The study performed vs. placebo was a short 
term (8 weeks), multicenter, randomized, 
double blind trial, performed on 503 patients, 
affected by episodes of major depression 
moderate/severe in degree (168 treated with 
agomelatine 25 mg/day, 169 with agomela-
tine 50 mg/day and 166 treated with place-
bo) [14]. The primary endpoint of the study 
was reduction of the score on the Hamilton 
Depression Rating Scale (HAM-D17) at the 
8th week. The 25 mg dose proved to be sta-
tistically more effective than the placebo 
(p=0.01); the 50 mg dose also proved to be 
statistically more effective than the placebo 
from the 2nd to the 6th week of treatment, but 
not at the 8th week. As to the secondary end-
points, patients treated with agomelatine 25 
mg showed a greater percentage of clinical 
response (p=0.013) and clinical remission 
(HAM-D17), than the group treated with the 
placebo; the same can be said for clinical 
improvement (CGI-I). The 50 mg dose did 
not demonstrate any statistical significance. 
The Hospital Anxiety and Depression Scale 
(HADS) score and the Leeds Sleep Evalua-
tion Questionnaire (LSEQ) quality of sleep 
score, improved significantly, compared to 
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the placebo, both with the 25 mg dose and 
with the 50 mg dose. Both agomelatine doses 
were well tolerated, with percentages of ad-
verse events that are identical for the three 
treatment groups. With the 50 mg dose, a 
temporary, but clinically relevant, increase 
of hepatic aminotransferase was found in 5 
patients.The studies performed vs. the active 
drug, comprise a short term (8 week), mul-
ticenter, international, randomized, double 
blind study performed on 515 pts (252 treat-
ed with agomelatine 25-50 mg/day and 263 
with fluoxetine 20-40 mg/day), with severe 
degree MDD (HAM-D17 basal values ≥ 25 
and CGI ≥ 4) [15]. The main objective of the 
trial was to reduce the HAM-D17 scale score 
after 8 weeks of treatment. The secondary ef-
ficacy assessments were based on CGI-S and 
HAM-A; an additional secondary assessment 
that concerned the quality of sleep was based 
on LSEQ. The average decrease of the total 
HAM-D17 scale score proved to be statisti-
cally greater (p=0.024) in the group treated 
with agomelatine compared to the fluoxetine 
group. Between the secondary endpoints, 
the percentage of responders at the 8th week 
( HAM-D17 and CGI-I) proved to be greater 
in the agomelatine group; moreover, a statis-
tically significant difference (p=0.018) was 
found in favor of agomelatine on the HAM-
D score for sleep items. The two medicines 
in the trial proved to be well tolerated, with 
similar percentages of side effects, which oc-
curred independently of the dosage used.
The other short term (6 weeks) study vs. ac-
tive drug, was a multicenter, international, 
randomized, double blind study performed 
on 313 patients (154 treated with agomela-
tine 25-50 mg/day and 159 with sertraline 
50-100 mg/day), with MDD of a moderate/
severe degree [16]. The primary objective 
of the study was evaluation of the Relative 
Amplitude (RA) of the individual rest-activ-
ity cycles (like the sleep-wake cycle index), 
measured by actigraphy; the secondary ob-
jectives, likewise measured by actigraphy, 
were sleep efficiency (the ratio between total 
sleeping time and time spent in bed), sleep la-
tency and efficacy on depression and anxiety 
symptoms evaluated with the HAM-D17, CGI 
and HAM-A scales. Agomelatine showed a 
statistically significant difference compared 
to sertraline, on the RA of the individual rest-
activity cycles after the first week (p=0.01), 
on sleep latency (p<0.001), and on sleep ef-
ficiency (p<0.001) from the 1st week to the 
8th week, as well as on depression symptoms 
(p<0.05) and anxiety symptoms (p<0.05). 
The two drugs under study proved to be well 
tolerated, with similar side effect percent-
ages, except for tiredness (5.9% agomelatine 
and 1.3% sertraline) and hyperhidrosis (5% 
sertraline and 0% agomelatine).
The long term study (24 weeks) was a mul-
ticenter, international, randomized, double 
blind trial performed on 138 patients (71 
treated with agomelatine 25-50 mg/day and 
67 with escitalopram 10-20 mg/day), with 
MDD of moderate/severe degree [17]. The 
polysomnographic results proved that treat-
ment with agomelatine was associated with 
a significant reduction in sleep latency com-
pared to escitalopram from the 2nd week up 
to the end of the assessment period. The ef-
ficiency of sleep was improved with agomel-
atine and, as far as sleep architecture was 
concerned, the REM (Rapid Eye Movement) 
latency significantly increased in the escita-
lopram group in all the visits carried out. In 
addition, agomelatine significantly preserved 
the number of sleep cycles compared to the 
marked decrease observed with escitalopram. 
The assessments performed with the analog 
scale showed an improvement of conditions 
upon awakening and decreased daytime 
drowsiness, in the group treated with agomel-
atine. The total score on HAM-D17, CGI-I 
and CGI-S decreased in a similar manner 
in the two groups. The two medicines under 
study proved to be well tolerated; agomela-
tine was associated with a significantly lower 
incidence of adverse events, as well as ad-
verse events considered to be associated with 
the treatment by the investigator.
Lastly, the study performed vs. active drug 
and placebo was a short term (8 weeks), ran-
domized, double blind trial, performed on 92 
healthy volunteers (23 treated with agomela-
tine 25 mg/day, 23 with agomelatine 50 mg/
day, 23 with paroxetine 20 mg/day and 23 
with placebo). The healthy volunteers repre-
sented an ideal group of subjects to assess for 
sexual dysfunction, in that they allowed for 
elimination of influences linked to depression 
[18]. The primary objective of the study was 
assessment of sexual dysfunction (SD) using 
the validated Psychotropic-Related Sexual 
Dysfunction Salamanca Sex Questionnaire 
(PRSEXDQ-SALSEX). At the 8th week, the 
SD proved to be significantly reduced in the 
agomelatine groups compared to the par-
oxetine group (p<0.0001). The percentage 
of volunteers with moderate or severe SD 
was 4.5% in the agomelatine group 25 mg, 
4.8% in the 50 mg group, 61.9% in the par-
oxetine group and 0% in the placebo group 
(p≤0.0001 agomelatine vs. paroxetine). The 
products under study were well tolerated and 
the assessments of hormonal profiles (prolac-
tin, total cortisol, free and total testosterone), 
did not show significant clinical variations 
compared to the placebo.
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architecture, sexual activity, and quality of 
life. Therefore, the branch to be selected is 
that relating to hard endpoints and quality of 
life (HE + QoL). The results are deemed to 
be excellent.
Harmful side effects
Once the effectiveness assessment has been 
completed, the algorithm takes into consider-
ation any serious harmful side effects that oc-
curred during the trial. In the case of agomel-
atine, no serious harmful side effects were 
reported. Therefore, as far as this assessment 
is concerned, the score is 0.
RESULTS
IAA-efficacy
In Table I the scores obtained with agomela-
tine are reported, based on selections made at 
the second level, proceeding on the decision 
tree through access to branch B.
On Table II the scores obtained with agomel-
atine are reported, based on the selections 
made on the third level.
Assigning the total score
The scores obtained in the first and second 
parts were added in order to calculate the final 
score obtained in the phase relating to effica-
cy assessment. The final score obtained for 
agomelatine is 592.73. Figure 9 shows the 
distribution of the maximum and minimum 
final scores that were obtained for each branch 
(A-F). The score decreases as the degree of 
innovation represented by each branch (A → 
F) decreases. For agomelatine, access to the 
algorithm occurs through branch B of thera-
peutic innovation: in fact, agomelatine is a 
new chemical entity which represents the pro-
Level Alternative Score
2.1 New action mechanism 200.00
2.2 Disease with high social impact 200.00
Total level 2 400.00
Table I. IAA- efficacy: agomelatine score on level 2, branch B
Level Alternative Score
3.1 Single therapeutic indication 16.80
3.2 Random, double blind controlled clinical trials 46.34
3.3 Population group: adults / all ages for whom 
drug use is indicated
25.80
3.4 Treatment of the disease 27.70
3.5 Type of clinical outcome obtained 76.09
Total level 3 192.73
Table II. IAA- efficacy: agomelatine score on level 3, branch B
Second Level
Level 2.1 – representative 
degree of the studies
This level provides a judgment relative to the 
international character of the studies and it is 
articulated in:
 - clinical trials based on enrollment of pa-
tients in an international context;
 - clinical trials based on the enrolment of 
patients at several trial sites within a sin-
gle country.
The studies, with the exception of one, were 
performed within an international context. 
Therefore, the selection falls on the upper 
branch.
Level 2.2 – quality of the research design
The level 2.2 of the algorithm provides for 
selecting the branch relating to the adequacy 
of the study protocol depending on the epide-
miological characteristics of the disease for 
which the drug is used. A guideline opinion 
(excellent, adequate, poor) is required of the 
research design. All the studies were random-
ized, prospective, double blind. However, the 
judgment that is issued is that of adequate, 
because elderly subjects were lacking within 
the population considered, and no interactive 
situations were considered. In addition, with 
the exception of a 24-week study, the term 
was never longer than 8 weeks.
Level 2.3 – degree of representativeness 
of the comparison drug
The parallel with the drugs selected for com-
parison, relative to the type of disease treat-
ed, may be classified as:
 - sufficiently representative;
 - not particularly representative;
 - not representative.
In this case the judgment is sufficiently rep-
resentative in that the studies were performed 
versus sertraline, escitalopram, paroxetine 
and fluoxetine which represent a great por-
tion of the current therapeutic stock in trade 
for major depression.
Level 2.4 – inclusion/exclusion criteria
The clinical experimentation proposed for 
IAA-effectiveness assessment may show:
 - inclusion and exclusion criteria present in 
the information given to the patient and 
the physician;
 - other inclusion and exclusion criteria not 
existing in the information given to the 
patient and to the physician, that may dif-
ferentiate the clinical and demographic 
characteristics of the population evalu-
ated from those regularly exposed to the 
treatment in clinical practice.
In this case, the inclusion/exclusion criteria 
described in the information about the drug 
were respected; therefore the upper branch is 
selected.
Third level
The third level is dedicated to chronic dis-
ease, therefore we can proceed to the fourth 
level.
Fourth level
Level 4.1 – number of patients enrolled
In the presence of an acute or sub-acute dis-
ease, the number of patients enrolled is taken 
into consideration in descending order:
 - more than 200 patients;
 - between 100 and 200 patients;
 - less than 100 patients.
The total number of patients treated with 
agomelatine in the 5 studies was 580 patients.
Level 4.2 – types of achievable objectives
This level allows for the selection of either 
treatment or control of the disease (in case 
of chronic disease) and the improvement of 
symptoms. As reported, agomelatine appears 
to have significantly greater therapeutic ef-
ficacy compared to the placebo or to the 
comparison drug not only in treating major 
depression by also in controlling some of its 
specific symptoms. At this level of the algo-
rithm, the upper branch is selected.
Level 4.3 – type of clinical 
outcome obtained
This level assigns a basic score to the types 
of outcomes and in this case as well a guide-
line opinion is required (excellent, sufficient, 
poor). As reported above, it can be seen that 
agomelatine appears effective for major de-
pression, both in terms of treating the dis-
ease, and in terms of improvement of sleep 
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totype of a new class, active against a pathol-
ogy (major depression) for which pharmaco-
logical therapies already exist.
Figure 10 shows the score obtained for the 
drug relative to the maximum and minimum 
score obtainable through access to branch B.
IAA-effectiveness
Table III shows the scores obtained for 
agomelatine based on the selections made at 
the second level.
Figure 9. Score obtained for agomelatine for each branch in the efficacy phase
Figure 10. Final score obtained for agomelatine in the efficacy phase
Level 2 Alternative Score
2.1 International studies 22.50
2.2 Quality of the research design 43.80
2.3 Representativeness of the comparison drug 52.50
2.4 Inclusion/exclusion criteria 22.50
Total level 2 141.30
Table III. IAA-effectiveness: agomelatine score on level 3
architecture, sexual activity, and quality of 
life. Therefore, the branch to be selected is 
that relating to hard endpoints and quality of 
life (HE + QoL). The results are deemed to 
be excellent.
Harmful side effects
Once the effectiveness assessment has been 
completed, the algorithm takes into consider-
ation any serious harmful side effects that oc-
curred during the trial. In the case of agomel-
atine, no serious harmful side effects were 
reported. Therefore, as far as this assessment 
is concerned, the score is 0.
RESULTS
IAA-efficacy
In Table I the scores obtained with agomela-
tine are reported, based on selections made at 
the second level, proceeding on the decision 
tree through access to branch B.
On Table II the scores obtained with agomel-
atine are reported, based on the selections 
made on the third level.
Assigning the total score
The scores obtained in the first and second 
parts were added in order to calculate the final 
score obtained in the phase relating to effica-
cy assessment. The final score obtained for 
agomelatine is 592.73. Figure 9 shows the 
distribution of the maximum and minimum 
final scores that were obtained for each branch 
(A-F). The score decreases as the degree of 
innovation represented by each branch (A → 
F) decreases. For agomelatine, access to the 
algorithm occurs through branch B of thera-
peutic innovation: in fact, agomelatine is a 
new chemical entity which represents the pro-
Level Alternative Score
2.1 New action mechanism 200.00
2.2 Disease with high social impact 200.00
Total level 2 400.00
Table I. IAA- efficacy: agomelatine score on level 2, branch B
Level Alternative Score
3.1 Single therapeutic indication 16.80
3.2 Random, double blind controlled clinical trials 46.34
3.3 Population group: adults / all ages for whom 
drug use is indicated
25.80
3.4 Treatment of the disease 27.70
3.5 Type of clinical outcome obtained 76.09
Total level 3 192.73
Table II. IAA- efficacy: agomelatine score on level 3, branch B
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Table IV shows scores obtained for agomela-
tine based on selections made at the fourth 
level.
Assigning the total score
The scores obtained on the second and fourth 
levels were added to calculate the final score 
obtainable in the phase relating to the effec-
tiveness assessment. The final score obtained 
for agomelatine is 291.3. Figure 11 shows the 
agomelatine score in the effectiveness phase 
relative to the maximum and minimum scores 
obtainable in the post-marketing assessment 
(not including ADV). 
Level 4 Alternative Score
4.1 Number of patients enrolled 67.50
4.2 Therapeutic results 22.50
4.3 Clinical results observed 60.00
Total level 4 150.00
Table IV. IAA-effectiveness: agomelatine score on level 4
Figure 11. Score obtained for agomelatine in the effectiveness phase
Assigning the total score (IAA-
efficacy + IAA-effectiveness)
The total score obtained for IAA-effective-
ness is added to the score obtained initially in 
the IAA-efficacy phase. Agomelatine re-
ceived a total score of 884. Figure 12 shows 
the score obtained for agomelatine in the ef-
ficacy phase + the effectiveness phase relative 
to maximum and minimum obtainable scores 
through access to branch B of the first phase. 
DISCUSSION
The innovation assessment algorithm assigns 
the highest score to new entities capable of 
treating pathologies for which no alterna-
tive therapies exist at the time (branch A of 
the Therapeutic Innovation). The maximum 
score that may be obtained by the efficacy 
assessment is 850 points. Access to the algo-
rithm through branches E and F of Industrial 
Innovation leads to obtaining lower scores 
(from a maximum of 380 points to a mini-
mum of 131). Agomelatine obtained a score 
of 592.73 which expresses a good degree of 
innovation. The factor that made the great-
est impact on the score was the new chemi-
cal structure of the molecule, not related to 
any pharmacological class currently used for 
major depression, with a new action mecha-
nism (melatoninergic agonist). This element, 
in a pre-registration phase, in which the fore-
casted impact of a new medicine on clinical 
practice is estimated, has an important role in 
determining the extent of innovation and has 
allowed for assigning a partial score of 400 
points to agomelatine. The remaining portion 
of the score (approximately 193 points) was 
obtained through the assessment of the clini-
cal studies performed, which showed in their 
overall results that agomelatine may be a val-
id alternative therapy for major depression.
In assessing IAA-effectiveness, we took into 
consideration additional post-registration 
studies on efficacy, on tolerability and on 
endpoints. These are indeed secondary, but of 
primary importance for this kind of disorder, 
as they include quality of life, the effect on 
sleep architecture, the lack of damaging ef-
fects of a sexual nature, and the like. The rep-
resentativeness of the sample presented was 
deemed adequate (approximately 580 patients 
treated with agomelatine). The same may be 
said for the types of studies, all RTC, both 
versus placebo, and versus the referenced 
drug. It is appropriate to stress that in two 
studies presented, the patients enrolled had 
a HAM-D ≥ 25 basal value, therefore, a se-
vere degree of the disorder. Moreover, in two 
studies agomelatine proved to be superior to 
the comparison drug either for the reduction 
Figure 12. Score obtained for agomelatine in the efficacy phase + the 
effectiveness phase
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of the HAM-D score or relative to the poly-
somnographic parameters as well as actig-
raphy findings and more generally for sleep 
architecture. The evaluation of no influence 
on sexual dysfunction during treatment with 
antidepressants was further confirmed by 
a comparison study versus paroxetine in 92 
healthy volunteers with significantly superior 
results in the group treated with agomelatine. 
The findings reported above confirm good 
efficacy and tolerability of agomelatine com-
pared to the placebo and to comparison medi-
cines, both for the improvement of depression 
symptoms and for equally important aspects 
such as sleep architecture and disturbances of 
a sexual nature. However, it is appropriate to 
stress the absence of adequate data relative to 
the length of treatment (maximum 8 weeks, 
excluding one 6-month study) as well as data 
concerning subpopulations such as, for ex-
ample, the elderly and/or patients with major 
depression also affected by other pathologies.
If we look at the overall agomelatine assess-
ment (IAA-efficacy + IAA-effectiveness), 
the score attributed to the maximum ob-
tainable through entry into branch B for ef-
ficacy, appears to be improved overall. The 
improvement is due in part to confirmation of 
the medicine’s efficacy and in part to the very 
low incidence and/or lack of serious adverse 
or potentially damaging side effects; this can 
be attributed to the peculiar action mecha-
nism of agomelatine which is safer compared 
to the SSRI, particularly in some potentially 
serious conditions such as, for example, sero-
tonergic syndrome.
CONCLUSIONS
This study reports an estimate of the degree 
of innovation for agomelatine (Valdoxan®/
Thymanax®), performed through the Innova-
tion Assessment Algorithm (IAA) on the ba-
sis of data supplied by Servier in support of 
its application for placement on the market, 
presented with a centralized procedure (IAA-
efficacy), and of additional post-registration 
studies (IAA-effectiveness). The Innovation 
Assessment Algorithm (IAA) allows one 
to attribute to each medicine an innovation 
value expressed in numerical terms, which 
derives from the sum of scores obtained by 
proceeding on the decision tree. Agomelatine 
obtained the score of 592.73 in the efficacy 
phase and 291.3 in the effectiveness phase; 
the total score for the two phases was 884, 
which corresponds to a good degree of inno-
vation of the molecule.
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